Chlamydia pneumoniae infection after lung transplantation

Glanville, Allan R.; Gencay, Mesut; Tamm, Michael; Chhajed, Prashant N.; Plit, M.; Hopkins, Peter; Aboyoun, Christina; Roth, Michael; Malouf, M.A.

doi:10.1016/j.healun.2003.09.042

Cited by 75 publications

(42 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…donor negative/ recipient positive) the risk of BOS was reduced. GLANVILLE et al [68] showed that C. pneumoniae infection in lung transplants was associated with a worse outcome and increased risk of BOS. One mechanism by which macrolide therapy may benefit lung transplant patients could be in the treatment of C. pneumoniae infection, but this issue remains bedevilled by the lack of a gold standard for this infection, as indicated earlier.…”

Section: Post-transplant Obliterative Bronchiolitismentioning

confidence: 99%

Long-term macrolide therapy in chronic inflammatory airway diseases

Crosbie¹,

Woodhead²

2008

Eur Respir J

120

View full text Add to dashboard Cite

In addition to direct antibacterial actions, 14-and 15-member-ring macrolides have immune modulating effects that appear to be the reason for clinical benefit in diffuse panbronchiolitis.A literature search was conducted for studies of the clinical effectiveness of macrolides in other chronic lung conditions.A number of studies were identified that showed short-term beneficial outcomes or the potential for such outcomes in cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, asthma and post-transplant obliterative bronchiolitis. The studies were limited by small patient numbers, different outcome measures and short-term follow-up, and were not designed to assess potentially harmful effects.Further large prospective and long-term studies are required in order to identify potential benefit and harm before these agents can be recommended routinely for these conditions.

show abstract

Section: Post-transplant Obliterative Bronchiolitismentioning

confidence: 99%

Long-term macrolide therapy in chronic inflammatory airway diseases

Crosbie¹,

Woodhead²

2008

Eur Respir J

120

View full text Add to dashboard Cite

show abstract

“…Acute rejection episodes or infections are recognized as risk factors for OB. 6 Obliterative bronchiolitis is characterized by epithelial and sub-epithelial inflammation predominating in the small airways, evolving in two successive phases. A phase of tissue injury involving leukocytes 7 precedes a phase of repair in which fibroblasts and growth factors generate peri-bronchiolar fibrosis, 8 leading to a fixed airways obstruction.…”

mentioning

confidence: 99%

Comparison of Induced Sputum and Bronchoalveolar Lavage in Lung Transplant Recipients

Mamessier¹,

Milhe

Badier

et al. 2006

The Journal of Heart and Lung Transplantation

View full text Add to dashboard Cite

“…Serological studies also described a positive correlation between C pneumoniae donor IgG antibodies and the development of BOS (191). Persistent infection with C pneumoniae (whether donor derived, de novo or reactivated) was also associated with allograft dysfunction in a prospective cohort study of 80 lung transplant recipients (192).…”

Section: Clinical Datamentioning

confidence: 92%

The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation

Martín-Gandul

Mueller

Pascual

et al. 2015

American Journal of Transplantation

134

103

View full text Add to dashboard Cite

Infectious diseases after solid organ transplantation (SOT) are a significant cause of morbidity and reduced allograft and patient survival; however, the influence of infection on the development of chronic allograft dysfunction has not been completely delineated. Some viral infections appear to affect allograft function by both inducing direct tissue damage and immunologically related injury, including acute rejection. In particular, this has been observed for cytomegalovirus (CMV) infection in all SOT recipients and for BK virus infection in kidney transplant recipients, for community-acquired respiratory viruses in lung transplant recipients, and for hepatitis C virus in liver transplant recipients. The impact of bacterial and fungal infections is less clear, but bacterial urinary tract infections and respiratory tract colonization by Pseudomonas aeruginosa and Aspergillus spp appear to be correlated with higher rates of chronic allograft dysfunction in kidney and lung transplant recipients, respectively. Evidence supports the beneficial effects of the use of antiviral prophylaxis for CMV in improving allograft function and survival in SOT recipients. Nevertheless, there is still a need for prospective interventional trials assessing the potential effects of preventive and therapeutic strategies against bacterial and fungal infection for reducing or delaying the development of chronic allograft dysfunction.

show abstract

Chlamydia pneumoniae infection after lung transplantation

Cited by 75 publications

References 35 publications

Long-term macrolide therapy in chronic inflammatory airway diseases

Long-term macrolide therapy in chronic inflammatory airway diseases

Comparison of Induced Sputum and Bronchoalveolar Lavage in Lung Transplant Recipients

The Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ Transplantation

Contact Info

Product

Resources

About